Award
National Institute on Aging 1R01AG088141-01A1
Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome
Recipient
Brigham and Women's Hospital, Boston, MA, United States
Award Amount
$801,359.00
Ceiling
$801,359.00
Awarded
September 08, 2025
Identifier
1R01AG088141-01A1
This NIH-funded phase 1 study investigates the safety and biological effects of NMN supplementation in adults with Down syndrome to address Alzheimer's disease pathology.
Description
A phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral Nicotinamide mononucleotide (NMN) in adults with Down syndrome to prevent or reverse Alzheimer's Disease progression.